| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/02/2009 | CN101522220A Long-term enteral feed for maintenance |
| 09/02/2009 | CN101518653A Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 09/02/2009 | CN101518650A Combination of a DPP IV inhibitor and a cardiovascular compound |
| 09/02/2009 | CN101518649A Compound preparation for treating ophthalmic infection and inflammation |
| 09/02/2009 | CN101518532A Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 09/02/2009 | CN100534997C C-aryl glucoside SGLT2 inhibitors and method |
| 09/02/2009 | CN100534530C Vehicle for topical delivery of anti-inflammatory compounds |
| 09/01/2009 | US7582762 Salt and crystalline forms of (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-YL)piperazin-1-YL]-2-hydroxypropoxy}quinoline |
| 09/01/2009 | US7582734 natural ligand for the orphan G-Protein Coupled Receptor (GPCR) ChemerinR and uses thereof in diagnosis and immuno therapy of a disease; monoclonal antibody; chemiattractant proteins; useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of GPCR signaling |
| 09/01/2009 | US7582476 For diagnosis and treatment of estrogenic disorder of mutant ER alpha |
| 09/01/2009 | US7582440 Imaging, diagnosis and treatment of disease |
| 09/01/2009 | US7582439 Detecting the presence/absence of a complex of a Bim molecule (a novel member of the Bcl-2 family) and an antibody specific for a specific amino acid sequence;modulating physiological cell death or survival and/or modulating cell cycle entry; antiapoptosis; anticarcinogenic agents; autoimmune diseases |
| 09/01/2009 | US7582315 Composition and method to augment and sustain neurotransmitter production |
| 09/01/2009 | US7582313 Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| 09/01/2009 | US7582311 Comprising hyaluronic acid or sodium hyaluronate dissolved in physiological buffer at concentration of 0.01-3 percent weight per volume and particles comprising first component biologically active agent and second component biocompatible polymeric matrix; use of 23-gauge or smaller bore needle |
| 09/01/2009 | US7582297 Methods of treating respiratory conditions |
| 09/01/2009 | US7582289 administering to proliferating cells in a mammal having a Ras-activated pathway a viruse selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus virus under conditions which result in lysis of neoplasmic cell |
| 09/01/2009 | US7582287 Method for treating cervical cancer |
| 09/01/2009 | CA2452432C Active ingredient combination for the pharmacological therapy of nicotine dependence |
| 09/01/2009 | CA2448689C Percutaneously absorbable patches |
| 09/01/2009 | CA2431206C Combination drugs containing anti-sepsis cycloalkene compound |
| 09/01/2009 | CA2420640C Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients |
| 09/01/2009 | CA2389411C Use of egfr tyrosine kinase inhibitor for preventing breast cancer |
| 09/01/2009 | CA2385867C Sustained release form comprising alpha-lipoic acid or derivatives thereof |
| 09/01/2009 | CA2379147C Percutaneously absorbable preparations |
| 09/01/2009 | CA2370556C Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 09/01/2009 | CA2308216C Use of non-immunosuppressive compounds for promoting nerve regeneration |
| 09/01/2009 | CA2274469C Serum-derived factor inducing cell differentiation and medical uses thereof |
| 08/27/2009 | WO2009104822A1 Medical preparation for retinal ischemia disorders, containing hydrogen molecules |
| 08/27/2009 | WO2009104388A1 Prophylactic/therapeutic agent for collagenosis |
| 08/27/2009 | WO2009104149A1 Combination comprising paclitaxel for treating ovarian cancer |
| 08/27/2009 | WO2009104045A1 Ophthalmic gemifloxacin compositions for the treatment of ocular infections |
| 08/27/2009 | WO2009103788A1 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 08/27/2009 | WO2009103727A2 Combination of an iron chelator and an immunosuppressant and use thereof |
| 08/27/2009 | WO2009103166A1 Treatment of neural diseases or conditions |
| 08/27/2009 | WO2009103160A1 Treatment and prevention of dry age-related macular degeneration by activating cd36 |
| 08/27/2009 | WO2009082038A3 Ampa receptor antagonists and zonisamide for epilepsy |
| 08/27/2009 | WO2009076455A3 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |
| 08/27/2009 | WO2009065395A3 Novel use of omega-3-fatty acid(s) |
| 08/27/2009 | WO2009063215A3 Use of crth2 antagonist compounds |
| 08/27/2009 | WO2009063202A3 Use of crth2 antagonist compounds |
| 08/27/2009 | WO2009026328A3 Methods of delivery of agents to leukocytes and endothelial cells |
| 08/27/2009 | WO2008142513A3 Phosphate-modified oligonucleotide analogs with immunostimulatory activity |
| 08/27/2009 | WO2008097861A3 MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS |
| 08/27/2009 | WO2008095093A3 Method of increasing cellular function and health of glutathione deficient animals |
| 08/27/2009 | US20090217400 Enzymes, cells and methods for site specific recombination at asymmetric sites |
| 08/27/2009 | US20090217392 Anti- integrin antibodies, compositions, methods and uses |
| 08/27/2009 | US20090217391 T1r3 a novel taste receptor |
| 08/27/2009 | US20090215813 Histone deacetylase inhibitors as immunosuppressants |
| 08/27/2009 | US20090215755 Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity |
| 08/27/2009 | US20090215714 Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder |
| 08/27/2009 | US20090215688 GLP-I Agonist And Cardiovascular Complications |
| 08/27/2009 | US20090215674 Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
| 08/27/2009 | US20090215089 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 08/27/2009 | US20090214669 Combination anticancer therapy and pharmaceutical compositions therefore |
| 08/27/2009 | US20090214637 Novel Gene Therapy Approach For Treating The Metabolic Disorder Obesity |
| 08/27/2009 | US20090214550 Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy |
| 08/27/2009 | US20090214492 Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| 08/27/2009 | US20090214479 Attenuated reovirus |
| 08/27/2009 | US20090214476 Novel mannose-specific adhesins and their use |
| 08/27/2009 | US20090214431 Identification of ergothioneine transporter and therapeutic uses thereof |
| 08/27/2009 | US20090214422 DNA encoding a novel RG1 polypeptide |
| 08/27/2009 | DE202008017304U1 Oral zerfallender Film zur therapeutischen Anwendung von Antiparasitika bei Tieren Oral disintegrating film for the therapeutic use of antiparasitic agents in animals |
| 08/27/2009 | CA2752851A1 Treatment and prevention of dry age-related macular degeneration by activating cd36 |
| 08/27/2009 | CA2750762A1 Treatment of neural diseases or conditions |
| 08/27/2009 | CA2715822A1 Combination of an iron chelator and an immunosuppressant and use thereof |
| 08/27/2009 | CA2714668A1 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 08/27/2009 | CA2714608A1 Combination comprising paclitaxel for treating ovarian cancer |
| 08/26/2009 | EP2093293A2 G-Protein coupled receptors |
| 08/26/2009 | EP2093292A2 Inhibition of specific histone deacetylase isoforms |
| 08/26/2009 | EP2093289A1 Knockout animal exhibiting anxiety-like behavior |
| 08/26/2009 | EP2093233A1 Novel compositions and methods in cancer |
| 08/26/2009 | EP2092940A1 Herbal medicine for osteoporosis and related conditions |
| 08/26/2009 | EP2092936A2 Tamper-resistant oral opioid agonist formulations |
| 08/26/2009 | EP2091967A1 Crystalline composition of gm-csf/gm-csfr |
| 08/26/2009 | EP2091566A1 Combination treatments for alzheimer's disease and similar diseases |
| 08/26/2009 | EP2091565A2 Method of diagnosing and treating glioma |
| 08/26/2009 | EP2091539A1 Ambrisentan combined with a renin inhibitor for hypertensive disorder |
| 08/26/2009 | EP2091521A1 Anticonvulsive pharmaceutical compositions |
| 08/26/2009 | EP2091336A2 Formulations comprising extracts from primitive plant species (mosses, ferns and lichens) to treat and prevent cancers |
| 08/26/2009 | EP1677772B1 Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action |
| 08/26/2009 | EP1539700B1 8-hydroxy quinoline derivatives |
| 08/26/2009 | EP1496929A4 Use of c5a receptor antagonist in the treatment of fibrosis |
| 08/26/2009 | EP1485087B1 (+)-2- [1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione for use in treating psoriasis by oral administration |
| 08/26/2009 | EP1478375B1 Compositions for the treatment of pilosebaceous gland inflammations comprising aluminium fluoride |
| 08/26/2009 | EP1450855B1 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 08/26/2009 | EP1389096B9 Delivery of opioids through an inhalation route |
| 08/26/2009 | EP1296714B1 Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. |
| 08/26/2009 | EP1283675A4 Methods of modulating the activity of mura |
| 08/26/2009 | EP1282636B1 Trp8, a transient receptor potential channel expressed in taste receptor cells |
| 08/26/2009 | EP1237915B1 Polynucleotid encoding the rg1 polypeptide |
| 08/26/2009 | EP1207879B1 Nicotine receptor agonists in stem cell and progenitor cell recruitment |
| 08/26/2009 | EP1012187B1 Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response |
| 08/26/2009 | CN101516401A Biomarkers for Alzheimer's disease progression |
| 08/26/2009 | CN101516400A Therapeutic agent for acceleration of spinal nerve repair comprising ghrelin, derivative thereof or substance capable of acting on GHS-R1a as active ingredient |
| 08/26/2009 | CN101516399A Therapeutic agent for acceleration of spinal nerve repair comprising desacyl ghrelin or derivative thereof as active ingredient |
| 08/26/2009 | CN101516375A Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors |
| 08/26/2009 | CN101516374A Histone deacetylase inhibitors with combined activity on class-I and class-IIB histone deacetylases in combination with proteasome inhibitors |
| 08/26/2009 | CN101516334A Stabilizing compositions for antibiotics and methods of use |
| 08/26/2009 | CN101513528A Compound chemotherapy medicament for treating liver cancer and multi-drug resistance tumor |